1. After 12 months of dual antiplatelet therapy in patients who received drug eluting stents (DES), patients who continued on a thienopyridine in addition to aspirin for 18 months experienced significantly lower rates of stent thrombosis and myocardial infarction compared to those taking placebo.
2. The risk of bleeding was significantly higher in patients who continued on thienopyridine therapy.
Original Date of Publication: December 2014
Study Rundown: Coronary revascularization with DES is increasingly used to treat ischemic heart disease. While DES reduce the risk of restenosis compared to bare metal stents (BMS), they are associated with a higher risk of stent thrombosis, which may result in myocardial infarction and death. After stenting, patients are treated with dual antiplatelet therapy in order to prevent progressive atherosclerosis of the stent itself and potential subsequent plaque rupture. The optimal duration of dual antiplatelet therapy to reduce the risk of stent thrombosis and atherosclerosis, while considering the increased risk of bleeding, is unknown. The purpose of the Dual Antiplatelet Therapy (DAPT) trial was to explore the effects of continuing dual antiplatelet therapy with a thienopyridine and aspirin for an additional 18 months in patients who had already been treated for 12 months.
In summary, the risk of stent thrombosis and myocardial infarction were significantly reduced in the group continuing dual antiplatelet therapy, compared to those being treated with placebo and aspirin. Patients continuing on dual antiplatelet therapy, however, also experienced significantly higher rates of bleeding. A major limitation of this study is that patients were only eligible for randomization if they were adherent with therapy and did not experience any cardiovascular or cerebrovascular events in the initial 12-month treatment period. As a result, patients who were randomized may be at lower risk of adverse events compared to the general population, thereby limiting generalizability. Notably, the study was funded by eight companies that manufacture stents and pharmaceuticals.
Click to read the study in the NEJM (New England Journal of Medicine)
EvidencePulse™by 2 Minute Medicine®
How does DAPT apply to your patient?
Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.
For a fuller review of the evidence, Deep research is a core feature of 2MM Max.
In-Depth [randomized controlled trial]: A total of 9 961 patients from 452 sites in 11 countries were randomized as part of this study. Patients were eligible for the trial if they were >18 years of age and could be treated with dual antiplatelet therapy after receiving DES (i.e., sirolimus-, zotraolimus-, paclitaxel-, or everolimus-eluting stents) or BMS. In this trial, only patients receiving DES were analyzed. All eligible patients were treated with a thienopyridine (i.e., clopidogrel 75 mg daily or prasugrel 10 mg daily) and aspirin for 12 months. Afterwards, patients who did not experience a major adverse cardiovascular or cerebrovascular event were randomized to continue treatment with a thienopyridine or a placebo until the 30-month mark, in addition to daily aspirin. The primary endpoints were the cumulative incidence of stent thrombosis and major adverse cardiovascular and cerebrovascular events (i.e., composite of death, myocardial infarction, and stroke) between months 12 and 30. The primary safety endpoint was the incidence of moderate or severe bleeding. Eight stent and pharmaceutical manufacturers were responsible for funding the study, though they did not have the right to make changes to the manuscript.
Patients who continued thienopyridine therapy experienced significantly lower rates of stent thrombosis when compared to those on placebo (HR 0.29; 95%CI 0.17-0.48). Moreover, the rate of major adverse cardiovascular and cerebrovascular events was also significantly lower in the thienopyridine group (HR 0.71; 95%CI 0.59-0.85). This was driven by significantly lower rates of myocardial infarction in the thienopyridine group (HR 0.47; 95%CI 0.37-0.61), as the rates of death from cardiovascular causes and stroke were similar in the two groups. With regards to safety, the risk of bleeding was significantly higher in the group that continued thienopyridine therapy as compared to placebo (HR 1.61; 95%CI 1.21-2.16). Notably, these differences were consistent regardless of the type of stent or thienopyridine used.
Trials since this one
What later trials found on the same question.
- 2015
Coronary CT angiography not superior to functional testing in cardiac risk management In The Classics
Computed tomographic coronary angiography (CTCA) as the initial diagnostic test for patients at intermediate risk of coronary artery disease (CAD) was not superior to functional cardiac testing with regard to all-cause…
- 2018
POINT In The Classics
In this randomized, controlled trial, combination therapy with aspirin and clopidogrel resulted in a lower risk of major ischemic events at 90 days versus aspirin alone for patients with acute ischemic stroke or…
2 more since 2014
2MM+ See every trial since DAPT
2MM+ shows the full timeline of later trials on this question, with what each one found, and lets you save trials to reading lists for rounds, journal club and boards.
Citation: Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/nejmoa1409312. Epub 2014 Nov 16. PMID: 25399658; PMCID: PMC4481318.
© 2015 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: PD

